Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Anna Åleskog"'
Autor:
Elin Lindhagen, Rolf Larsson, Caroline Haglund, Lena Håkansson, Anna Åleskog, Martin Höglund, Stefan Jacobsson
Publikováno v:
Toxicology Letters. 194:102-107
One of the most common dose limiting adverse effects in cancer treatment is myelotoxicity. The aim of this study was to develop an in vitro method for measuring potential myelotoxic properties of a drug candidate in a high throughput setting. Human C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d833368bff17d0de3eab74b5571ca01e
https://doi.org/10.1016/j.toxlet.2010.02.006
https://doi.org/10.1016/j.toxlet.2010.02.006
Autor:
Richard Rosenquist, Anna Åleskog, Mats G. Gustafsson, Maria Norberg, Christer Sundström, Elin Lindhagen, Magnus Åberg, Gerard Tobin, Meena Kanduri, Laura Säisänen
Publikováno v:
European Journal of Haematology. 83:22-34
Chronic lymphocytic leukemia (CLL) is a heterogeneous malignancy displaying varying clinical outcome, where molecular markers today can divide patients into prognostic subgroups. Despite the introduction of new agents for treatment, remissions are us
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c800354e2a1723c81495ed2ac374de3
https://doi.org/10.1111/j.1600-0609.2009.01248.x
https://doi.org/10.1111/j.1600-0609.2009.01248.x
Autor:
Karin Karlsson, Gerard Tobin, Mohd Arifin Kaderi, Göran Roos, Mats Merup, Mattias Jansson, Anna Åleskog, Fiona Murray
Publikováno v:
Leukemia Research. 32:984-987
Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease with no known single predisposing genetic factor shown in all cases. Recently, a single nucleotide polymorphism (SNP) T393C in the GNAS1 gene has been reported to have a clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a929489745c5647140ac2ddc2a230fb
https://doi.org/10.1016/j.leukres.2007.10.003
https://doi.org/10.1016/j.leukres.2007.10.003
Autor:
Tomas Axelsson, Mohd Arifin Kaderi, Christer Sundström, Gerard Tobin, Anna Åleskog, Fiona Murray, Maria Norberg, Karin Karlsson, Göran Roos, Mats Merup, Richard Rosenquist
Publikováno v:
Leukemia. 22:339-343
The (-938C>A) polymorphism in the promoter region of the BCL-2 gene was recently associated with inferior time to treatment and overall survival in B-cell chronic lymphocytic leukemia (CLL) patients displaying the -938A/A genotype and may thus serve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1d4a90c84d6ef92367658cfbf63a16e
https://doi.org/10.1038/sj.leu.2405042
https://doi.org/10.1038/sj.leu.2405042
Publikováno v:
Toxicology in Vitro. 21:1174-1181
Several in vitro methods have been suggested to predict drug-induced haematotoxicity and species differences; the most commonly used being the clonogenic CFU-GM assay. The aim of the current study was to evaluate whether primary lymphocytes from peri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e015860ffca8e6eb7c0e27643f0026c
https://doi.org/10.1016/j.tiv.2007.03.009
https://doi.org/10.1016/j.tiv.2007.03.009
Autor:
Lorenzo M. Leoni, Peter Nygren, Linda Rickardson, Elin Lindhagen, Gary Elliott, Anna Åleskog, Rolf Larsson
Publikováno v:
Investigational New Drugs. 25:297-303
SDX-308 and SDX-309 are potent indole-pyran analogues of SDX-101 (R-etodolac) which has anti-tumour activity unrelated to cyclooxygenase-2 inhibition. Their cytotoxic activity was further studied herein using a well-characterized human tumour cell-li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab7f22b8dea6219be3ffb739bc7cd3ae
https://doi.org/10.1007/s10637-007-9049-4
https://doi.org/10.1007/s10637-007-9049-4
Autor:
Rolf Larsson, Elin Lindhagen, Bengt Simonsson, Ulla Olsson-Strömberg, Mats Bengtsson, Gisela Barbany, Martin Höglund, Anna Åleskog, Anneli Björnberg
Publikováno v:
Anti-Cancer Drugs. 17:631-639
The aims of this study were to evaluate the feasibility of using the non-clonogenic fluorometric microculture cytotoxicity assay in drug sensitivity testing of tumor cells from patients with chronic myeloid leukemia. In nine samples (six chronic phas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b38a67722cfde5214229b22b0c029a97
https://doi.org/10.1097/01.cad.0000217423.59831.db
https://doi.org/10.1097/01.cad.0000217423.59831.db
Autor:
Gerard Tobin, Mats Merup, Juhani Vilpo, Karin Karlsson, Göran Roos, Hartmut Döhner, Dirk Kienle, Christer Sundström, Helena Jernberg-Wiklund, Ulf Thunberg, Anna Åleskog, Richard Rosenquist, Anna Laurell, Alexander Kröber, Karin Nilsson, Stephan Stilgenbauer, A Skogsberg
Publikováno v:
Leukemia. 20:77-81
The G(-248)A polymorphism in the promoter region of the Bax gene was recently associated with low Bax expression, more advanced stage, treatment resistance and short overall survival in B-cell chronic lymphocytic leukemia (CLL), the latter particular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::729e5be5c91a3850c0993c4b3c58f4ab
https://doi.org/10.1038/sj.leu.2404030
https://doi.org/10.1038/sj.leu.2404030
Autor:
Gerard Tobin, Peter Nygren, Elin Lindhagen, Christer Sundström, Anna Laurell, Anna Åleskog, Ulf Thunberg, Kenneth Nilsson, Martin Höglund, Göran Roos, Rolf Larsson, Richard Rosenquist
Publikováno v:
European Journal of Haematology. 73:407-411
Objective: B-cell chronic lymphocytic leukaemia (B-CLL) can be divided into two clinical entities based on the immunoglobulin variable heavy chain (V H ) gene mutation status, as cases with unmutated V H genes display a more aggressive disease with s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6af81d1957478d6002289d585573b58f
https://doi.org/10.1111/j.1600-0609.2004.00334.x
https://doi.org/10.1111/j.1600-0609.2004.00334.x
Autor:
Anna Åleskog, Elin Jonsson, Christer Sundström, Martin Höglund, Jörgen Kristensen, Rolf Larsson, Peter Nygren
Publikováno v:
British Journal of Haematology. 117:563-568
Summary. Evaluating the potential benefit of the new anthracycline, idarubicin (Ida), in lymphoma, 58 tumour samples from patients suffering from low-grade non-Hodgkin's lymphoma (L-NHL), were analysed in vitro for their sensitivity to 0·5 µg/ml Id
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad65bd84d8a4f174634ede47b259eb24
https://doi.org/10.1046/j.1365-2141.2002.03484.x
https://doi.org/10.1046/j.1365-2141.2002.03484.x